Comparative Pharmacology
Head-to-head clinical analysis: EMPAGLIFLOZIN versus JARDIANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAGLIFLOZIN versus JARDIANCE.
EMPAGLIFLOZIN vs JARDIANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
Sodium-glucose co-transporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, lowering blood glucose independent of insulin.
10 mg orally once daily, with or without food; may increase to 25 mg once daily if eGFR ≥60 mL/min/1.73 m² and additional glycemic control needed.
10 mg orally once daily, may increase to 25 mg orally once daily if tolerated and additional glycemic control needed.
None Documented
None Documented
Terminal elimination half-life is approximately 12.4 hours (range 10-18 h) in patients with T2DM; supports once-daily dosing.
Clinical Note
moderateEmpagliflozin + Gatifloxacin
"Empagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateEmpagliflozin + Rosoxacin
"Empagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateEmpagliflozin + Levofloxacin
"Empagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateEmpagliflozin + Trovafloxacin
"Empagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.9 hours in healthy subjects. Steady-state is achieved after 4-5 days of once-daily dosing. Effective half-life for accumulation: ~4-6 hours.
Renal (54% as unchanged drug) and fecal (41% as unchanged drug or metabolites); biliary excretion is minimal.
Primarily renal: approximately 70-80% of absorbed dose excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal: ~10-20% via biliary and fecal elimination.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor